Welcome to our dedicated page for TransCode Therapeutics news (Ticker: RNAZ), a resource for investors and traders seeking the latest updates and insights on TransCode Therapeutics stock.
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) is a Boston-based clinical-stage biopharmaceutical company dedicated to combating metastatic disease through the discovery, development, and commercialization of novel microRNA (miRNA) therapeutics. The company's pioneering work centers around its proprietary TTX nanoparticle platform, designed to effectively deliver RNA-based therapies to target and treat various cancers.
The lead therapeutic candidate of TransCode Therapeutics, TTX-MC138, focuses on metastatic tumors that overexpress microRNA-10b, a well-known biomarker associated with metastasis. This candidate is currently undergoing rigorous clinical trials, with initial results indicating promising accumulation of the therapy in metastatic lesions.
The company also boasts a diverse pipeline of RNA therapeutic candidates, including TTX-siPDL1 and TTX-RIGA, aimed at overcoming the delivery challenges of RNA therapies and addressing novel genetic targets relevant to different cancer types. TransCode is actively engaged in expanding its research collaborations, as highlighted by its project combining the TTX platform with Debiopharm’s drug delivery technologies.
However, TransCode faces noteworthy financial and regulatory challenges. Recent communications reveal that the company is addressing compliance issues with Nasdaq listing requirements and the potential need for a reverse stock split to maintain its listing status. Despite these hurdles, TransCode remains committed to advancing its research and development efforts, securing strategic partnerships, and raising sufficient capital to drive its innovative pipeline forward.
TransCode’s vision extends beyond treating metastatic cancer; they aim to revolutionize cancer therapy by creating highly selective treatments that trigger the immune response against tumors while sparing healthy tissues. This approach is exemplified by their tumor-selective RIG-I agonists currently in development.
TransCode Therapeutics (Nasdaq: RNAZ) has secured a $2.3 million funding from a Fast-Track SBIR grant to continue clinical development of TTX-MC138, its lead candidate for treating advanced solid tumors.
The second tranche of this funding was activated following the achievement of a program milestone in Q1 2022, which contributed $1.1 million to the company. The CEO has confirmed plans to submit an eIND for a first-in-human study this year, aiming to validate the novel delivery platform targeting microRNA-10b, implicated in metastatic disease.
TransCode Therapeutics (Nasdaq: RNAZ) will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, with a live presentation scheduled for May 24 at 7:00 a.m. ET. CEO Michael Dudley will highlight the Company’s RNA-based innovations aimed at advancing cancer treatment, including the upcoming First-in-Human trial for its lead candidate, TTX-MC138, planned for late 2022. This candidate targets metastatic disease, responsible for about 90% of cancer deaths globally. The presentation will be available via live feed and on-demand.
TransCode Therapeutics (NASDAQ: RNAZ) has signed an option agreement to negotiate an exclusive license for a radiotheranostic technology aimed at enhancing cancer treatment. Developed by Dr. Zdravka Medarova and her team at Massachusetts General Hospital, this technology involves radiolabeled nanoparticles that could improve diagnostics and therapeutic capabilities. CEO Michael Dudley expressed optimism about integrating this technology with their existing RNA delivery system, TTX. TransCode plans to submit an exploratory IND application to initiate a Phase 0 First-in-Human trial for TTX-MC138 in late 2022.
TransCode Therapeutics (NASDAQ: RNAZ) reported its Q1 2022 financial results, highlighting a cash position of $16.9 million. The company plans to submit an exploratory IND application for its lead candidate, TTX-MC138, in a Phase 0 study targeting advanced solid tumors. Financially, expenses rose significantly, with R&D costing $1.9 million and a total operating loss of $3.5 million. TransCode achieved a milestone in its SBIR grant and aims for further funding to support ongoing projects and team expansions, while also filing for new patents in RNA oncology.
TransCode Therapeutics (NASDAQ: RNAZ) announced that Dr. Zdravka Medarova will moderate the 7th Annual RNA Medicine Symposium on April 28, 2022. The event, co-sponsored by Harvard Medical School and Beth Israel Deaconess Medical Center, will feature esteemed speakers from various prestigious institutions. Dr. Medarova will also present at the 3rd Annual RNAi-Based Therapeutics Summit, discussing novel siRNA-based therapies for cancer, including their applications and the potential of RNAi in tumor targeting. TransCode aims to advance RNA oncology therapeutics to improve patient outcomes.
TransCode Therapeutics (NASDAQ: RNAZ) announced its financial results for 2021 and highlighted significant business advancements.
Key achievements included an over-subscribed IPO raising $28.8 million and the award of a $2.3 million SBIR grant for the clinical evaluation of its lead candidate, TTX-MC138.
The company plans to submit an eIND application to the FDA for TTX-MC138 and initiate a Phase 0 study in Stage IV cancer patients in 2022. As of December 31, 2021, TransCode had $20.8 million in cash, sufficient to fund operations into early 2023.
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced that an interview with CEO Michael Dudley will be broadcasted on The RedChip Money Report® on Bloomberg TV on March 26 at 7 p.m. ET. The report aims to provide insights into small-cap investing and features financial commentary and public company interviews. TransCode focuses on RNA therapeutics to combat cancer, with lead candidate TTX-MC138 targeting metastatic cancer. This condition accounts for about 90% of cancer deaths globally, totaling over nine million annually.
TransCode Therapeutics (NASDAQ: RNAZ) published an article in Cancers discussing the advancements in short RNA-based therapeutics for cancer and other diseases. Co-authored by Dr. Anna Moore, the article explores the design, modification, and delivery of these RNA drugs. Key insights include the potential of RNA therapeutics to revolutionize treatment methods, particularly in personalized cancer therapy. CEO Michael Dudley announced plans for a first-in-human trial of the lead candidate, TTX-MC138, aimed at targeting metastatic disease, which accounts for 90% of cancer deaths.
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has filed an International PCT Application (PCT/US21/65580) for its novel cancer therapy entitled TEMPLATE DIRECTED IMMUNOMODULATION FOR CANCER THERAPY. This application expands the company's RNA therapeutic platform to activate the RIG-I signaling pathway, potentially leading to tumor cell death and enhancing the immune response against cancer. The patent aims to allow for personalized cancer treatments using TransCode's TTX delivery platform, which targets various RNA therapies for different tumor types.
TransCode Therapeutics (Nasdaq: RNAZ) has announced its participation at the 2022 BIO CEO & Investor Conference, scheduled for February 14-17, 2022. CEO Michael Dudley will present the company's RNA-based innovations aimed at combating cancer, particularly highlighting the lead candidate, TTX-MC138, intended for metastatic disease treatment. An exploratory Investigational New Drug (eIND) application with the FDA is expected to be filed in the second half of 2022 to initiate a first-in-human trial for Stage IV breast cancer patients.
FAQ
What is the current stock price of TransCode Therapeutics (RNAZ)?
What is the market cap of TransCode Therapeutics (RNAZ)?
What does TransCode Therapeutics, Inc. specialize in?
What is TTX-MC138?
What are the challenges TransCode Therapeutics is facing?
What is the significance of the TTX nanoparticle platform?
What recent project involves TransCode’s TTX platform?
What is the clinical status of TTX-MC138?
How does TransCode aim to innovate cancer therapy?
What are some other RNA therapeutic candidates in TransCode’s pipeline?
Who can I contact for more information about TransCode Therapeutics?
What are TransCode’s goals for 2024?
